drugset
drugset / Trial / NCT04846998

A Study to Compare the Pharmacokinetics of BR9003A and BR9003 in Healthy Adult Subjects

NCT04846998 ↗

Phase 1 Completed 24 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of oral administration of BR9003 compared with BR9003A in healthy adult subjects

Timeline

Start
2021-03-25
Primary completion
2021-05-04
Completion
2021-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject BR9003 Unknown 2 mg Oral
Subject BR9003A Unknown 1 mg Oral

Indications

No indication recorded.